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Abstract
The effect of nontoxic, low concentrations (1038 M) of retinoic acid (RA) for a relatively long time (28 days) on a Kirsten
ras-virus transformed cell line (Ki-SVC1), derived from the rat seminal vesicle epithelium, was investigated. In these
experimental conditions, the cell treatment with RA induced a decrease of the proliferation rate, apoptosis and a marked
reduction of both anchorage-independent growth and tumorigenicity. These biological responses were either preceded or
associated with important changes in adenylate cyclase/protein kinase C signaling pathways, the activation of important
apoptosis-linked genes and a marked decrease of the v-Ki-ras p21 protein. The significance of these findings is
discussed. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
A major goal of biology today is the prevention
and reversion of the malignant cell phenotype. ras
genes have been involved in the transformation of
many cell types [1^3]; moreover ras genes are mu-
tated in 20^30% of human tumors and the encoded
proteins are believed to contribute to the pathogen-
esis of these malignancies.
We have previously reported that in a Kirsten
ras-virus transformed cell line, derived from rat semi-
nal vesicle epithelium (Ki-SVC1), adenylate cyclase
(AC) activity was markedly enhanced in comparison
to that occurring in the normal counterpart as a
consequence of an unbalanced Ks/Ki modulation [4].
Since it is well known that AC and cAMP are
involved in the regulation of cell growth and
di¡erentiation and since there is experimental evi-
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dence that the AC/protein kinase C (PKC) and ras/
mitogen-activated protein kinase (MAPK) signaling
pathways can cross-talk each other and both with
the retinoic acid (RA)/RAR gene system [5^7], we
were prompted to treat the Ki-SVC1 cells with
RA, a potent bio-e¡ector possessing the ability to
modulate growth, di¡erentiation and apoptosis in a
variety of normal or transformed cells [8], in an at-
tempt to negatively interfere with their malignant
features.
The biological properties of RA have been used
both in cell cultures and in vivo to induce signi¢cant
and stable reversion of the malignant phenotype [9].
Therapeutic protocols, di¡erent in treatment time-
length and RA concentration, were used with varia-
ble success in various leukemia types [9]. The occur-
rence of important side-e¡ects and adverse reactions
was a serious drawback for the adoption of this bio-
active chemical in cancer therapy [9]. At present,
however, emerging data and further experimentation
is leading to new perspectives for a more advanta-
geous use of RA in this speci¢c therapeutic ¢eld [10].
In this context we were prompted to add RA in
the culture medium of a transformed cell line in or-
der to ¢nd the best conditions of RA treatment (time
length and concentration) to produce the maximal
reversion of the malignant features with the minimal
RA concentrations.
Consistent with this experimental design, we
treated the Ki-SVC1 cells for di¡erent lengths of
time (3^28 days) with several concentrations (1036,
1037 and 1038 M) of RA in order to study the bio-
logical e¡ects of this treatment. A marked decrease
of malignancy was found to occur in the cells treated
for 28 days with 1038 M RA, an experimental con-
dition producing the desired anti-tumoral e¡ects with
the minimal RA concentration in the absence of the
cytotoxic e¡ects of higher, non-physiological concen-
trations [11,12]. The RA-induced biological e¡ects
(growth arrest, apoptosis, decrease of anchorage-in-
dependent cell growth, reduction of tumorigenicity,
more di¡erentiated aspects of the induced tumors)
were accompanied by important changes in AC/
PKC signaling pathways, a substantial decrease of
v-Ki-ras p21 protein and the activation of some im-
portant genes (p53, c-myc and tTGase) of the apop-
tosis gene expression program. The signi¢cance of
these ¢ndings is discussed.
2. Materials and methods
2.1. Materials
[K-32P]ATP (29.6 TBq/mmol) and [Q-32P]ATP (111
TBq/mmol) were obtained from Du Pont-New Eng-
land Nuclear, whereas all-trans RA was purchased
from Sigma (St. Louis, MO, USA). The source of
other materials is reported where appropriate.
2.2. Cell culture, anchorage-independent growth in
soft agar and tumorigenicity
The Ki-SVC1 cells, a Kirsten ras-virus trans-
formed cell line derived from the rat (Wistar^Fischer
strain) seminal vesicle epithelium, were cultured at
37‡C in a 5% CO2 humidi¢ed atmosphere in Dulbec-
co’s modi¢ed Eagle’s medium (DMEM) containing
10% fetal calf serum and changing the medium every
2 days [13]. When required, the cells were treated
with appropriate dilution in DMEM of an all-trans
RA stock solution in dimethyl sulfoxide (DMSO).
For both RA-treated and -untreated cells the ¢nal
DMSO concentration in the culture medium was
1.2 mM. In the experiments in which the cells were
treated with RA for di¡erent lengths of time (3^28
days), the RA-containing medium was changed every
48 h. The cell number was assessed by a Burker
hemocytometer. The cell viability was routinely as-
sessed by phase-contrast light microscopy, trypan
blue exclusion test and, where required, TUNEL
(see Section 2.3). The e¡ect of the RA-treatment on
the biological properties of the ras-transformed cells
was evaluated by measuring their ability to produce
colonies in soft agar (anchorage-independent growth
in soft agar assay) [14] or tumors in vivo after sub-
cutaneous injection of 2.5U105 or 106 viable RA-
treated or -untreated Ki-SVC1 cells in newborn syn-
geneic rats (Wistar^Fischer). The controls used in the
di¡erent enzymatic and biological assays, were RA-
untreated Ki-SVC1 cells harvested after the appro-
priate number of days in culture. No signi¢cant dif-
ferences were observed among the di¡erent controls
analyzed.
2.3. Apoptosis detection
Labelling for apoptotic cells was carried out ac-
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cording to the manufacturer’s instructions using the
Apoptosis Detection System, Fluorescein Kit (Prom-
ega Corporation, Madison, WI, USA). This method
exploits terminal deoxynucleotidyl transferase-medi-
ated dUTP nick end labelling (TUNEL) of double or
single stranded breaks induced in DNA in cells
undergoing apoptosis. Labelled, apoptotic cells
were visualized directly by £uorescence microscopy
and counted.
2.4. DNA fragmentation analysis
Genomic DNA isolation and agarose gel electro-
phoresis analysis were performed as elsewhere de-
scribed [15].
2.5. RNA isolation and semi-quantitative RT-PCR
analysis
Total RNA, isolated by RNAZOL B (Biotec Lab-
oratories) from Ki-SVC1 cells before and after treat-
ment with di¡erent RA concentrations, was tran-
scribed into complementary DNA (cDNA) by
reverse transcriptase (Superscript II, Gibco-BRL) ac-
cording to the manufacturer’s protocol. Six hundred
ng of cDNA were ampli¢ed in a reaction mixture
containing, in a ¢nal volume of 50 Wl, 10 mM
Tris^HCl (pH 8.3), 1.5 mM MgCl2, 50 mM KCl,
100 ng of both sense and antisense primers for either
murine bcl-2 (sense 5P-AACACCAGAATCAAGT-
GTTC-3P and antisense 5P-TTCCCTTTGGCAGT-
AAATAG-3P), murine p53 (sense 5P-CCCTTCTCA-
AAAAACTTACC-3P and antisense 5P-TCATAA
CAAGCCCTAAAGTC-3P) or human L-actin (sense
5P-ATCCAGGCTGTGTTGTCCCTG-3P and anti-
sense 5P-AGGAGCCAGGGCAGTAATCTC-3P),
200 mM dNTP and 2.5 U Taq DNA polymerase
(Boehringer Mannheim). The sense and antisense
primers used (100 ng each) for human tTGase,
murine c-myc and murine v-Ki-ras were: tTGase
(sense 5P-TCAAGTATGGCCAGTGCTGGGTCT-
TCGC CG-3P and antisense 5P-TTAAACTGGCTC-
CACGAGGA-3P), c-myc (sense 5P-AACTTACAA-
TCTGCGAGCCA-3P and antisense 5P-AGCAGCT-
CGAATTTCTTCCAGATAT-3P) and v-Ki-ras (sense
5P-TTTTACACAGCCAGGAGTCT-3P and anti-
sense 5P-TAGTGGCGTAGGCAAGAGT G-3P).
The reaction was carried out in a DNA thermal cy-
cler (Perkin Elmer-Cetus Instruments). The PCR re-
actions were performed in the exponential phase of
ampli¢cation and started always with a 3 min dena-
turation step at 95‡C. For p53, bcl-2 and tTGase
32 cycles (95‡C, 30 s; 55‡C, 1 min; 72‡C, 1 min)
were used, whereas 32 or 27 cycles (95‡C, 45 s;
50‡C, 45 s; 72‡C, 1 min) were used for c-myc and
ras, respectively. In all cases a ¢nal step of 7 min at
72‡C was used. The PCR products were analyzed by
electrophoresis on 1.2% agarose gel in TAE (tris^
acetate^EDTA) bu¡er [15]. The identity of the am-
pli¢cation products was con¢rmed both by direct nu-
cleotide DNA sequencing and comparison of their
size with the size expected from the known gene se-
quence. Co-ampli¢cation of di¡erent cDNA sequen-
ces with L-actin was performed in order to have a
semi-quantitative evaluation of p53, c-myc and Ki-ras
p21 gene expression. The L-actin primers were added
in the ampli¢cation reaction mixture seven cycles lat-
er than the other primers, in order to allow all of the
ampli¢cations to occur in the exponential phase of
the reaction, well below the plateau conditions.
2.6. cAMP, AC and PK assays
Intracellular cAMP was extracted as previously
described [16] and measured by a radioimmunologi-
cal assay (Amersham).
Cell membranes and cytosol were prepared from
monolayer cells as previously reported [17]. The AC
assay was performed according to a published radio-
metric procedure [18,19]. The protein kinase (PK)
and the PKC activities were evaluated according to
a standard radiometric technique [17]. As enzyme
sources, we used the proteins of either a cytosolic
(supernatant after centrifugation at 27 000Ug for
20 min at 4‡C) or a membrane (sediment at
27 000Ug for 20 min of the supernatant obtained
by centrifugation at 900Ug for 10 min) fraction of
a cell homogenate and in some experiments we used
proteins partially puri¢ed by DEAE^cellulose chro-
matography [20].
2.7. Immunodetection of v-Ki-ras p21 protein
Proteins from cell preparations were separated by
SDS^PAGE (10 or 12%) [21] and transferred onto
nitrocellulose sheets (Schleicher and Schuell) by a
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Fig. 1. Ki-SVC1 transformed cells (panel A) and their ability to produce colonies in vitro (growth in soft agar; panel D and inset) and tumors in vivo (panel E; in
panel F is shown an excised tumor). Morphological and biochemical aspects of RA-induced apoptosis of Ki-SVC1 cells treated for 25 days with 1037 M RA: panel
C shows the electrophoretic pro¢le of 1 mg genomic DNA extracted from RA-treated or -untreated KI-SVC1 cells (lane 1: untreated Ki-SVC1 cells ; lane 2: 1 mg of
low MW DNA markers (100 bp ladder, from Boehringer); lane 3: RA-treated Ki-SVC1 cells with clear DNA fragmentation features); panel B shows Ki-SVC1 apop-
totic cells.
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Trans-Blot apparatus (BioRad). v-Ki-Ras p21 pro-
teins were detected from a total cell homogenate
(see above), clari¢ed from nuclei by centrifugation
at 900Ug for 10 min at 4‡C, by using both a mono-
clonal antibody anti-Ki-ras (F234) directed against a
speci¢c epitope within amino acid residues 163^179
(Santa Cruz Biotechnology, CA, USA) and a mono-
clonal anti Ki-ras (Ab-1) directed against a speci¢c
epitope within amino acid residues 54^189 (Onco-
gene). II Goat anti-rabbit or anti-mouse antibodies,
conjugated with alkaline phosphatase or with horse-
radish peroxidase (BioRad), were used as a detection
system according to the manufacturer’s instructions.
2.8. Evaluation of protein concentration
Protein concentration was determined according to
Bradford [22].
2.9. Statistical analysis
The data have been reported as means þ S.D.
(standard deviation) obtained from three separate
experiments in which each point was performed in
triplicate. The means were compared using analysis
of variance (ANOVA) plus Bonferroni’s t-test and a
P-value of less than 0.05 was considered signi¢cant.
3. Results
3.1. RA treatment decreases the Ki-SVC1
tumorigenicity
The Ki-SVC1 cells (Fig. 1A) produced colonies in
soft agar (Fig. 1D) and were tumorigenic when inoc-
ulated in newborn syngeneic rats (Fig. 1E,F and Ta-
ble 1). In particular, the subcutaneous injection of
106 cells induced at the inoculation site the appear-
ance of undi¡erentiated tumors whose histologic
con¢guration resembled an angiosarcoma. No meta-
stases were detectable. If not surgically excised, the
tumors killed the animals within one month. The
biological characteristics of the Ki-SVC1 cells
changed after treatment with 1038M RA. In fact,
after 26 days of treatment their tumorigenicity and
growth were decreased by about 65 and 35%, respec-
tively (Table 1), the tumors were more di¡erentiated
and the tumor-a¡ected animals survived longer. Sim-
ilar results were obtained by treating the cells with
1037 or 1036 M RA for 26 or 6^7 days, respectively.
(Table 1). In particular, the progressive increase of
RA concentration produced a progressive decrease of
tumorigenicity.
3.2. RA treatment reduces Ki-SVC1 cell growth and
promotes apoptosis
After 21 days of cell growth in the absence or
presence of 1037 or 1038 M RA, growth curves
were established by counting treated or untreated
cells every day, for a further 7 days. The data re-
ported in Fig. 2 show that the number of untreated
cells progressively increased reaching a plateau, ex-
pression of cell con£uence, between the 27th and the
28th day of incubation. By contrast, the number of
cells treated with 1038 M RA regularly increased
between the 22nd and 25th day of treatment, reach-
ing thereafter a plateau that was still evident on the
28th day of treatment (Fig. 2). These cells never
reached the con£uence phase. A similar growth inhi-
bition, even though earlier and more severe, was ob-
served when cells were treated with 1037 or 1036 M
Fig. 2. E¡ect of RA treatment on Ki-SVC1 cell growth. The
cells (105) were grown in monolayer (see Section 2) in the ab-
sence (E) or in the presence of either 10^8 (P) or 10^7 (7) M
RA.
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RA (Fig. 2 and Table 1). In particular, at the latter
concentration the cells began to detach and die by
apoptosis at the 3rd^4th day of treatment. After a
further 3 days of treatment (6th^7th day) about 70%
of the cells were apoptotic, 10^15% were necrotic
(Table 1) and the surviving cells had their doubling
time prolonged from one to about three days (not
shown). At all the RA concentrations used, the de-
crease of cell proliferation was associated with mor-
phological and biochemical signs of apoptosis (Fig.
1, panels B,C and Fig. 3, panels a,b,c). In particular,
the data reported in Fig. 3 show that the c-myc
mRNA amount increased signi¢cantly already after
3 days of RA treatment, whereas the p53 and tTGase
mRNA levels increased after 14 and 28 days of treat-
ment, respectively. This increase of mRNAs, as de-
termined by semi-quantitative reverse transcription-
polymerase chain reaction (RT-PCR), could be
related to a transcription-dependent event, even
though an increase of mRNA stability could not be
ruled out. Other data (not shown) indicated that the
mRNA coding for bcl-2 was not detectable during
the entire experimental period in both treated and
untreated cells.
3.3. RA treatment induces a decrease in the amount of
viral Ki-ras p21 protein not associated with
changes in the level of mRNA coding for this
protein
The level of the v-Ki-ras p21 protein, immunolog-
ically detected, decreased up to 50% between the 14th
and the 28th day of RA treatment (Fig. 3, panel d),
while the immunological detection of L-actin, used as
internal control, did not show any change (data not
shown). To verify whether this decrease was related
to possible changes in the Ki-ras gene transcriptional
activity induced by the RA treatment, the amount of
v-Ki-ras mRNA in RA-treated or -untreated Ki-
SVC1 cells was measured by using a semi-quantita-
tive RT-PCR protocol with primers possessing the
ability to discriminate between v-Ki-ras and c-Ki-
ras mRNA. The data reported in Fig. 3 (panel c)
indicate that the transcriptional activity of this gene
remained apparently unchanged during the entire ex-
perimental treatment. Consequently, the observed
decreased amount of the Ki-ras p21 protein was
most probably related to a reduced stability of the
protein.
Table 1
Biological events induced by the treatment of Ki-SVC1 cells with di¡erent RA concentrations for di¡erent lengths of timea
Cell treatment Biological events
cell growth inhibition (%) apoptotic cellsb (%) tumorigenicityc
Untreated* 0.000 2^4 þ 1 36/36
1038 M RA (26th day) 35 þ 3** 40 þ 5** 13/36**
1037 M RA (26th day)d 100 þ 4** 60 þ 7** 8/36**
1036 M RA (6^7th day)d 100 þ 6** 75 þ 4** 5/36**
*Untreated Ki-SVC1 cells, harvested at up to 28 days of culture, were used as controls. No signi¢cant di¡erences were observed
among the di¡erent controls.
**P6 0.001 versus the respective untreated control value.
aExperimental details are reported Section 2.
bThe percentage of apoptotic cells was evaluated by the TUNEL method.
cRats with tumors/total number of rats.
dIt is worth knowing that at these RA concentrations a signi¢cant percentage (10^15%) of the cell population was necrotic, as de-
tected by phase-contrast light microscopy and trypan blue exclusion test. The presence of necrotic cells indicates the occurrence of cy-
totoxic e¡ects. The parameters used to identify the necrotic cells were: marked cell swelling, nuclei uniformly dense or barely visible,
cytoplasm granular or ¢nely vacuolated, rupture and dissolution of plasma and nuclear membranes, dramatic decrease of cell viability,
presence of amorphous debris due to cell disintegration, etc.
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3.4. RA treatment with a higher concentration (1036)
and for a shorter time induces a decrease in the
amount of viral Ki-ras p21 protein
To further prove the correlation between RA
treatment and v-Ki-ras p21 protein level down-regu-
lation, we treated transformed cells with an RA con-
centration 100-fold higher up to 72 h, just before the
occurrence of cell detachment and death. Moreover,
since it is well known that levels of many proteins
Table 2
Adenylate cyclase activity of Ki-SVC1 cells treated or not with 1038 M RAa
Addition pmol cAMP/mg protein/min
untreated RA-treated (3 days) RA-treated (28 days)
None (basal activity) 79 þ 2.3 129 þ 6.1** (63) 98 þ 3.7* (24)
Forskolin (1035 M) 400 þ 11 6O4 þ 27** (51) 405 þ 19 (0)
NaF (1032 M)b 206 þ 9.4 362 þ 12** (76) 245 þ 10* (19)
*P6 0.05; **P6 0.001 versus the respective untreated control value.
aFor experimental details, see Section 2. The AC activity of untreated cells (controls) cultured for 0, 3 or 28 days did not show signi¢-
cant £uctuations. The values reported in the table represent the mean þ S.E.M. of three independent experiments performed in tripli-
cate.
bThe AC activity measured in the presence of NaF refers to the G-protein stimulated AC activity. The values placed within brackets
indicate the percentage increase in the AC activity of RA-treated versus untreated cells.
Fig. 3. Evaluation by RT-PCR of di¡erent mRNAs (encoding for p53, c-myc, tTGase, Ki-ras p21) and immunological detection (im-
munoblotting) of the Ki-ras p21 protein at di¡erent times (0, 3, 14 and 28 days) of RA treatment. Experimental details are reported
in Section 2. Panel a: lanes 1^4 (0, 3, 14 and 28 days, respectively) refer to p53 mRNA; lane 5 refers to low MW DNA markers (100
bp ladder); lanes 6^9 (0, 3, 14 and 28 days, respectively) refer to c-myc mRNA; in this panel the bands of the middle row refer to
b-actin mRNA (internal control). Panel b: lanes 1^4 refer to tTGase mRNA levels at 0, 3, 14 and 28 days of RA treatment; lane 5
refers to DNA markers (see above). Panel c: the bands of the upper row refer to L-actin mRNA (see arrow), whereas the bands of
the lower row refer to Ki-ras p21 mRNA at 0, 3, 14 and 28 days of RA treatment (lanes 1^4); lane 5 refers to low MW DNA
markers (100 bp ladder). Panel d: immunoblots of the Ki-ras p21 protein from total cell extract (20 Wg) at di¡erent times of RA
treatment; lanes 1^4 (0, 3, 14 and 28 days, respectively); lane 5: negative control from the SVC1 untransformed cells. A quantitative
evaluation of the results was obtained by densitometric analysis.
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involved in cell growth control are a¡ected by cell
density, we also investigated the v-Ki-ras p21 protein
levels in asynchronously growing versus con£uent
cells. The results, shown in Fig. 4, indicate that
v-Ki-ras p21 protein level is strongly lowered during
the time course, while the v-Ki-ras p21 protein level
is signi¢cantly increased in untreated control cells
during the same time course. To note that in these
conditions control untreated cells became con£uent
between 48 and 72 h as monitored by the cyclin A
(Cyc A) decrease and the cyclin-dependent-kinase
(CDK) inhibitor p27 protein increase [23]. As far
as the changes of these cell cycle markers in the
RA-treated cells are concerned, they re£ect the ef-
fects on cell growth induced by RA.
3.5. RA treatment increases adenylate cyclase (AC)
activity and intracellular levels of cAMP
After 3 days of cell treatment with 1038 M RA
both the basal AC activity (Table 2) and the intra-
cellular level of cAMP of Ki-ras-transformed cells
almost doubled. A similar increase in the AC activity
of RA-treated cells was also observed after in vitro
forskolin or G-protein stimulation. A time course of
the AC activity measured in RA-treated cells showed
a ¢rst peak of activity after 48 h of treatment fol-
lowed by a decrease to basal level after 7 days of
treatment (Fig. 5). A second wave of increase was
detectable between the end of the second week and
the 31st day of treatment with the maximum increase
at the 28th day of treatment (Fig. 5). The two peaks
of AC activity were associated with biologically-rel-
evant biochemical events.
3.6. 1038 M RA treatment decreases cytosolic and
membrane-bound Ca2+-dependent and increases
cytosolic Ca2+-independent PKC activities
The time course of the cytosolic Ca2-dependent
Fig. 4. Regulation of v-Ki-ras p21 protein levels by cell density
and by RA treatment. Ki-SVC1 transformed cells (2U106 cells/
10 cm plate) were plated and cultured for the indicated times in
the absence (control) or in the presence of 1036 M RA with
medium changes every day. Total cell extracts were prepared at
each time point. Twenty Wg of each lysate were subjected to
SDS^PAGE (12%), transferred to nitrocellulose membrane and
blotted with antibodies against the indicated proteins, using the
ECL (Amersham) detection system according to the manufac-
turer’s directions.
Table 3
Ca2-dependent and Ca2-independent protein kinase C (PKC) activities of untreated or RA (1038 M)-treated Ki-SVC1 cellsa
PKC pmol [32P] incorporated/mg protein/min
untreated RA-treated (3 days) RA-treated (28 days)
Cytosol
Ca2-dependent 1890 þ 52 1270 þ 39** 1000 þ 35**
Ca2-independent 730 þ 30 (39) 1120 þ 43** (88) 980 þ 24** (98)
Membrane
Ca2-dependent 560 þ 25 310 þ 19** 360 þ 22**
Ca2-independent 230 þ 20 (41) 250 þ 15 (81) 215 þ 10 (60)
**P6 0.001 versus the respective untreated control value.
aPKC activity was always determined in the presence of suitable concentrations of phosphatidyl-serine and diacyl-glycerol. The PKC
activity was calculated by subtracting the enzymatic activity determined in the absence of stimulating cofactors (phosphatidyl-serine,
diacyl-glycerol and Ca2 where required) from that determined in the presence of these cofactors. The PKC activity of untreated cells
(controls), cultured up to 28 days, remained substantially unmodi¢ed. The numbers placed within brackets refer to the Ca2-indepen-
dent/Ca2-dependent PKC activity ratio expressed in percent.
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PKC activities of RA-treated or -untreated cells (Ta-
ble 3) shows a dramatic decrease after 3 days and a
further, progressive decrease up to the 28th day of
treatment. After 3 days of treatment the level of
membrane bound Ca2-dependent PKC activities
also were markedly reduced. The decrease was still
detectable after 28 days of treatment.
On the other hand, the cytosolic Ca2-independent
PKC activities signi¢cantly increase after 3 days of
RA treatment. These increased activities were still
maintained after 28 days of treatment. No signi¢cant
changes were detectable concerning the membrane
bound Ca2-independent PKC activities.
4. Discussion
The data reported here show that a long-term
treatment (26^28 days) of transformed Ki-SVC1 cells
with 1038 M RA produced important biological
modi¢cations associated with a number of biochem-
ical events. More precisely, the long term treatment
of 1038 M RA of transformed Ki-SVC1 cells de-
creased the tumorigenicity, reduced the cell growth
and promoted apoptosis. The acquisition of this
‘less-transformed’ phenotype was accompanied by
profound biochemical modi¢cations: an early in-
crease of both AC activity and cAMP amount, a
decrease of Ca2-dependent and an increase of
Ca2-independent PKC activities and down-regula-
tion of v-Ki-ras p21 protein levels. The changes in
the AC/PKC signaling pathways occurring in the
RA-treated Ki-SVC1 cells are biochemical events
that are frequently associated with down-regulation
of cell proliferation in ongoing processes of di¡er-
entiation and in successful antineoplastic therapies
[8,24^29]. The observed increase of cAMP, in fact,
by up-regulating the cAMP-dependent protein kinase
(PKA) activity, could play an important role in the
modulation of the phosphorylation status and activ-
ity of several regulatory proteins belonging to the
p21ras^Raf1^MAPK signaling pathway involved in
cell growth and di¡erentiation control [3,30,31].
As far as p21ras proteins are concerned, it is
known that ras proteins, H-, K- and N-ras, occupy
pivotal positions in signal transduction processes that
send replication signals from the cell’s plasma mem-
brane to the nucleus. ras genes are mutated in 20^
30% of human cancers and the encoded proteins are
believed to contribute to the pathogenesis of these
malignancies [32]. The viral p21 protein, frozen in a
permanent activated state by speci¢c point muta-
Fig. 5. Time course of adenylate cyclase activity (pmol of cAMP/mg protein/min) of Ki-SVC1 cells at di¡erent times of RA treatment.
Experimental details are described in Section 2.
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tions, plays two important roles in the Ki-SVC1
cells : (1) support of their high proliferation rate by
keeping the p21ras^Raf1^MAPK signaling pathway
continuously on; (2) negative modulation of apopto-
sis by acting at several levels, including the speci¢c
biochemical processes that regulate the caspase-
fueled proteolytic cascade [33]. Moreover, it has
been described that down-regulation of p21ras func-
tion, either by microinjection of v-Ki-ras p21 block-
ing antibodies [34], or by using drugs negatively af-
fecting farnesyltransferase (FTase) activity [35] (an
enzyme involved in the membrane translocation
and functional activation of ras proteins), causes re-
version of malignant phenotype. Therefore, the de-
crease of the v-Ki-ras p21 protein, observed in our
hands, could represent a key event in the chain of
biochemical processes that lead to the observed RA-
induced biological phenomena, even though the
mechanism of its decrease and the activation of the
programmed cell death (PCD) would still remain to
be explained and is currently under our investigation.
Some experimental observations on the ability of RA
to inhibit the FTase activity [36] can, however, help
in ¢nding a more complete interpretation of our re-
sults. The activated proteolytic activity in the cells
undergoing apoptosis could then decrease the
amount of v-Ki-ras p21, whose function was possibly
already altered by the long-lasting inhibitory action
of RA on FTase [36]. We have investigated the pos-
sibility that RA treatment could cause a decrease of
v-Ki ras p21 protein by a¡ecting the protein trans-
location from the cytosol to the membrane but, at
least in the conditions indicated in Fig. 4, the total
v-Ki-ras p21 protein decrease was accompanied by
an almost equivalent decrease in both membrane
and cytosolic fractions (data not shown). Of course
our ¢nding does not exclude that more exhaustive
experiments could catch the moment in which v-Ki-
ras p21 protein is increased in the cytosol an de-
creased in the membrane. Anyway, the reduction in
the amount and function of the v-Ki-ras p21 protein,
typically endowed with strong anti-apoptotic proper-
ties [33], would then start a sort of ‘virtuous cycle’
consisting of further reduction of the cell prolifera-
tion rate, an increase in susceptibility to apoptosis
and activation of di¡erentiation processes. The acti-
vation of this cycle would eventually lead, in con-
junction with the modi¢cation of the AC/PKC path-
ways simultaneously occurring, to a substantial
decrease of the malignancy properties of our exper-
imental model. We also have found (see Fig. 3, panel
b) an increase of tTGase gene expression associated
with the appearance of susceptibility to apoptosis in
our cell population. The up-regulation of this gene is
also in agreement with both the documented role
played by tTGase in the apoptotic process and the
reported inverse relationship between its activity and
malignancy [37^39].
Overall in our experiments we observed the sup-
pression of both RA-induced anchorage-independent
growth and tumorigenicity after a long-term (about 4
weeks) treatment of the v-Ki-ras transformed SVC1
cells with low doses of RA and in parallel we ob-
served a down-regulation of p21ras protein levels.
The interference with the p21ras^Raf1^MAPK path-
way has been proposed as a strategy for developing
new anticancer agents [40]. Our ¢ndings of the down-
regulation of the p21ras protein and of modi¢cations
of AC/PKC pathways by RA treatment, could pro-
vide new insight into the role of RA as an antipro-
liferative agent and might suggest a possible function
of RA as an anticancer drug also in those tumors
sustained by ras-protein overexpression.
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